{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:00:46Z","timestamp":1775487646384,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"LOGIC project","award":["2022.04138.PTDC"],"award-info":[{"award-number":["2022.04138.PTDC"]}]},{"name":"LOGIC project","award":["2022.00943.CEECIND"],"award-info":[{"award-number":["2022.00943.CEECIND"]}]},{"name":"LOGIC project","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Foundation for Science and Technology (FCT)","doi-asserted-by":"publisher","award":["2022.04138.PTDC"],"award-info":[{"award-number":["2022.04138.PTDC"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Foundation for Science and Technology (FCT)","doi-asserted-by":"publisher","award":["2022.00943.CEECIND"],"award-info":[{"award-number":["2022.00943.CEECIND"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Foundation for Science and Technology (FCT)","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"P.CCC: Centro Compreensivo de Cancro do Porto","award":["2022.04138.PTDC"],"award-info":[{"award-number":["2022.04138.PTDC"]}]},{"name":"P.CCC: Centro Compreensivo de Cancro do Porto","award":["2022.00943.CEECIND"],"award-info":[{"award-number":["2022.00943.CEECIND"]}]},{"name":"P.CCC: Centro Compreensivo de Cancro do Porto","award":["NORTE-01-0145-FEDER-072678"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-072678"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Gastric and gastroesophageal junction adenocarcinomas (GA\/GEJA) are associated with a poor prognosis, primarily due to late disease diagnosis. Human Epidermal Growth Factor Receptor 2 (HER2) overexpression and programmed death-ligand 1 (PD-L1) expression are important biomarkers for treatment selection in locally advanced unresectable and metastatic GA\/GEJA, and there is increasing interest in their role in earlier stages of disease. In this study, we aimed to evaluate HER2 and PD-L1 expression in a curative-intent GA\/GEJA cohort to describe their expression patterns and analyze the association between HER2 expression and clinicopathological features. HER2 expression was evaluated in surgical and endoscopic submucosal dissection tumor samples, and PD-L1 was evaluated in HER2-positive cases. The clinical cohort included 107 patients, with 8.4% testing positive for HER2 (seven of whom also exhibited a PD-L1 combined positive score of \u22651. HER2 status was not significantly associated with survival outcomes. A pathologist-guided, region-specific analysis revealed that PD-L1 expression rarely overlaps with HER2-positive tumor areas. While the therapeutic implications of these observations remain unknown, these findings suggest that combination strategies targeting HER2 and PD-L1 might be directed toward distinct tumor subclones. The herein disclosed region-specific biomarker expression patterns may have important therapeutic and prognostic impacts, warranting further evaluation.<\/jats:p>","DOI":"10.3390\/cancers16061227","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T13:09:36Z","timestamp":1710940176000},"page":"1227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["HER2 and PD-L1 Expression in Gastric and Gastroesophageal Junction Cancer: Insights for Combinatorial Targeting Approaches"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-1419","authenticated-orcid":false,"given":"Marta Baptista","family":"Freitas","sequence":"first","affiliation":[{"name":"Department of Medical Oncology of Unidade Local de Sa\u00fade (ULS) de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"}]},{"given":"Irene","family":"Gullo","sequence":"additional","affiliation":[{"name":"Department of Pathology of Unidade Local de Sa\u00fade (ULS) de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), 4200-329 Porto, Portugal"},{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto (i3S), 4200-135 Porto, Portugal"}]},{"given":"Dina","family":"Leit\u00e3o","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), 4200-329 Porto, Portugal"}]},{"given":"L\u00facia","family":"\u00c1guas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology of Unidade Local de Sa\u00fade (ULS) de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Faculty of Medicine of the University of Porto (FMUP), 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-2264","authenticated-orcid":false,"given":"Carla","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto (i3S), 4200-135 Porto, Portugal"},{"name":"Faculty of Medicine of the University of Porto (FMUP), 4200-319 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-1681","authenticated-orcid":false,"given":"Ant\u00f3nio","family":"Pol\u00f3nia","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto (i3S), 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal"},{"name":"Instituto de Investiga\u00e7\u00e3o, Inova\u00e7\u00e3o e Desenvolvimento, Funda\u00e7\u00e3o Fernando Pessoa (FP-I3ID), 4249-004 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8832-2703","authenticated-orcid":false,"given":"Joana","family":"Gomes","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto (i3S), 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-1006","authenticated-orcid":false,"given":"F\u00e1tima","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Department of Pathology of Unidade Local de Sa\u00fade (ULS) de S\u00e3o Jo\u00e3o, 4200-319 Porto, Portugal"},{"name":"Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), 4200-329 Porto, Portugal"},{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto (i3S), 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-6639","authenticated-orcid":false,"given":"Celso Albuquerque","family":"Reis","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto (i3S), 4200-135 Porto, Portugal"},{"name":"Faculty of Medicine of the University of Porto (FMUP), 4200-319 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal"},{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar (ICBAS), Universidade do Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-8368","authenticated-orcid":false,"given":"Henrique Oliveira","family":"Duarte","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto (i3S), 4200-135 Porto, Portugal"},{"name":"Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"ref_1","unstructured":"(2024, March 18). Globocan Cancer Observatory. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/7-Stomach-fact-sheet.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Alsina","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/jso.26844","article-title":"Advances in screening and detection of gastric cancer","volume":"125","author":"Xia","year":"2022","journal-title":"J. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","article-title":"Current developments in gastric cancer: From molecular profiling to treatment strategy","volume":"20","author":"Alsina","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"153229","DOI":"10.1016\/j.prp.2020.153229","article-title":"Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer","volume":"216","author":"Zhang","year":"2020","journal-title":"Pathol. Res. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gas-tro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1007\/s00262-023-03566-5","article-title":"Current state of the art: Immunotherapy in esophageal cancer and gastroesophageal junction cancer","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: Recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Narita, Y., and Muro, K. (2023). Updated Immunotherapy for Gastric Cancer. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072636"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fon-2020-0737","article-title":"First-line pem-brolizumab\/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811","volume":"17","author":"Chung","year":"2021","journal-title":"Future Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"ESMO Gastric Cancer Living Guideline v1.2 October, 2023","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_19","unstructured":"(2023, November 08). FDA Amends Pembrolizumab\u2019s Gastric Cancer Indication. U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-amends-pembrolizumabs-gastric-cancer-indication."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA A Cancer J. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Marletta, S., Fusco, N., Munari, E., Luchini, C., Cimadamore, A., Brunelli, M., Querzoli, G., Martini, M., Vigliar, E., and Colombari, R. (2022). Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. J. Pers. Med., 12.","DOI":"10.3390\/jpm12071073"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: An emerging paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"(2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513, 202\u2013209.","DOI":"10.1038\/nature13480"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-16-2211","article-title":"Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project","volume":"23","author":"Sohn","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s12253-020-00814-2","article-title":"PD-L1 and HER2 Expression in Gastroesophageal Cancer: A Matched Case Control Study","volume":"26","author":"Beer","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","article-title":"Updates on global epidemiology, risk and prognostic factors of gastric cancer","volume":"29","author":"Yang","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Marano, L., Verre, L., Carbone, L., Poto, G.E., Fusario, D., Venezia, D.F., Calomino, N., Ka\u017amierczak-Siedlecka, K., Polom, K., and Marrelli, D. (2023). Current Trends in Volume and Surgical Outcomes in Gastric Cancer. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072708"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.dld.2022.01.128","article-title":"PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance","volume":"54","author":"Lian","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Pous, A., Notario, L., Hierro, C., Layos, L., and Bug\u00e9s, C. (2023). HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Ther-apeutic Strategies. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202306.0932.v1"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/6\/1227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:16:52Z","timestamp":1760105812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/6\/1227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cancers16061227"],"URL":"https:\/\/doi.org\/10.3390\/cancers16061227","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}